US Grant

BARDA

Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, was established to aid in securing our nation from chemical, biological, radiological, and nuclear (CBRN) threats, as well as from pandemic influenza (PI) and emerging infectious diseases (EID).

Subsidy: no max.

Funding rate: 100%

Deadlines: Expired

Project duration: max. 5 years; project specific

Consortium: Applicants can be from any country. Applicants may include single entities or teams from private sector organizations, government laboratories, and academic institutions.

Scope: Support advanced development activities of medical countermeasures for influenza and other emerging respiratory viruses to be specified by BARDA. BARDA is also prioritizing broadly reactive immunotherapeutics, such as monoclonal antibodies, that will be effective in treating severely ill, hospitalized patients of all ages who are infected with influenza or other emerging infectious diseases.

 

More US Grants

 


About BARDA

BARDA supports the transition of medical countermeasures such as vaccines, drugs, and diagnostics from research through advanced development towards consideration for approval by the FDA and inclusion into the Strategic National Stockpile. BARDA’s support includes funding, technical assistance and core services, ranging from a clinical research organization network to Centers for Innovation in Advanced Development and Manufacturing, and a fill-finish manufacturing network. To-date, BARDA has supported 42 FDA approvals for products addressing CBRN, PI, and EID threats. Visit the SNN website for more information.

BARDAs mission is accomplished through successful public-private partnerships with industry to share risk, improve efficiency and accelerate development all while sustaining a marketplace that guarantees continued access to countermeasures vital to their national security.

Visit the website for more information

 


About Catalyze

Catalyze is an innovation consultancy offering services to develop effective strategy, procure (non-) dilutive funding, ensure successful project delivery, and more, for clients working in the fields of life sciences & health, and green & sustainable innovations. Driven by a belief that the most meaningful innovations deserve the best chance to succeed, Catalyze has established itself as a key player in the innovation ecosystem, headquartered in Amsterdam and operating worldwide. To date, Catalyze has raised more than €1 billion in funding for its clients, built a network ecosystem of more than 2500 partners, and manages a €300M+ project portfolio.

Newsletter

A must-have if you’re interested in getting your business to the next level